RxDoctor Payments Data

Ryan Cronin, DO

Vascular Surgery · Kingsport, TNNPI 1942612643

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.4%), education and grants — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Medtronic at 40.2% of the total.

$8,534in general payments, 2019–2025

Across 143 payments — averaging $59.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • W. L. Gore & Associates, Inc.$2K
  • Cook Medical LLC$833
  • Bolton Medical Inc$437
  • Inari Medical, Inc.$405
  • Silk Road Medical, Inc.$397
  • plus $1K from 16 others

What the payments were for

  • Grants$1,66720%
  • Travel & lodging$3594%
  • Food & beverage$4,72655%
  • Education$1,78221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,534 in reported general payments places this provider in the 55th percentile of 117 vascular surgery providers in Tennessee.

See all vascular surgery providers in Tennessee

Medicare billing

Part B allowed, 2024
$71,659
Medicare patients
316
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban43$24,949
EliquisApixaban15$16,406
Cilostazol177$4,594
ClopidogrelClopidogrel Bisulfate155$1,393
Pentoxifylline13$541
Enoxaparin Sodium13$520
Rosuvastatin Calcium16$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$24,94943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 117 vascular surgery providers in Tennessee.

Other vascular surgery in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →